Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Dexcom (DXCM) Acquisitions (2021 - 2022)

Dexcom has reported Acquisitions over the past 2 years, most recently at $700000.0 for Q3 2022.

Quarterly Acquisitions fell 97.78% to $700000.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $700000.0 through Jun 2023, down 97.9% year-over-year, with the annual reading at $3.9 million for FY2022, 87.09% down from the prior year.
Acquisitions was $700000.0 for Q3 2022 at Dexcom, down from $3.2 million in the prior quarter.
Over five years, Acquisitions peaked at $31.6 million in Q3 2021 and troughed at -$1.4 million in Q4 2021.